Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc., No. 14-1671 (Fed. Cir. May 13, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Classen Immunotherapies, Inc. (“Classen”) appeals from the decision of the United States District Court for the District of Maryland granting summary judgment that Elan Pharmaceuticals, Inc. (“Elan”) did not infringe U.S. Patent 6,584,472 (“the ’472 patent”) based on the safe harbor provision of 35 U.S.C. § 271(e)(1). See Classen Immunotherapies, Inc. v. King Pharm., Inc. , 466 F. Supp. 2d 621 (D. Md. 2006) ( granting summary judgment); Classen Immunotherapies, Inc. v. King Pharm., Inc. , 981 F. Supp. 2d 415 (D. Md. 2013) ( denying reconsideration).